Part A and B: Advanced Solid Malignancies Clinical Trial
Official title:
A Ph1 Open-Label Multicentre Study to Assess Safety, Tolerability, PK and Anti-tumor Activity of Tremelimumab /Tremelimumab With MEDI4736 in Japanese With Advanced Solid Malignancies or Tremelimumab in Japanese With Malignant Mesothelioma
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, PK and Preliminary Anti-tumor Activity when given as a monotherapy of Tremelimumab or Tremelimumab in combination with MEDI4736 in Japanese Patients with Advanced Solid Malignancies, and when given as a monotherapy of tremelimumab in Second- or Third-line Treatment of Japanese Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
Primary objectives Part A: To investigate the safety and tolerability of tremelimumab when
given to Japanese patients with advanced solid malignancies and define the dose(s) for
further clinical evaluation.
Part B: To investigate the safety and tolerability of tremelimumab in combination with
MEDI4736 when given to Japanese patients with advanced solid malignancies and to define the
dose(s) for further clinical evaluation.
Part C: To investigate the safety and tolerability of tremelimumab when given to Japanese
patients with unresectable pleural or peritoneal malignant mesothelioma.
;